A new study suggests that roughly half of the opioid prescriptions written by dentists in the United States exceed the three-day supply recommended by federal dental pain-management guidelines.
The research also showed that during the five-year study period, a more powerful narcotic than necessary was prescribed almost 3 times of out 10.
The findings, published today in the American Journal of Preventive Medicine , are important because dentists are responsible for 10% of all opioids prescribed in the United States, which has been in the throes of an opioid-fueled public health crisis for more than two decades.
"Dental procedures like extractions can leave patients with a lot of pain that needs to be managed, and many dentists are doing a wonderful job of managing their patients' pain appropriately and responsibly," said Jessina McGregor, a researcher in the Oregon State University College of Pharmacy who took part in the study. "But our findings suggest that there's room for improvement among some dentists, improvement that could make a huge difference in our society as we try to combat the opioid crisis."
Traced to over-prescribing that began in the 1990s, the opioid epidemic claims more than 40,000 American lives per year, according to the U.S. Department of Health and Human Services. Ten million people a year misuse prescription opioids, and 2 million suffer from an opioid use disorder.
Occurring naturally in the opium poppy, opioids are a class of drugs that block pain signals between the body and brain and also make some people feel relaxed, happy or high. They can be highly addictive and exist both as prescription painkillers like hydrocodone and oxycodone and street drugs such as heroin.
The research collaboration that included McGregor and was led by Katie Suda of the University of Pittsburgh assessed more than half a million adult dental visits from 2011 to 2015 within the Truven Health MarketScan Research Databases. Related Stories
Also in Industry News
How to decide whether or not to start treatment for prostate cancer?
Analysis of the SARS-CoV-2 proteome via visual tools
$65m investment increases British Patient Capital’s exposure to life sciences and health technology